NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK(TM) Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Stock Information for INVO BioScience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INVO BioScience Inc.

INVO Reports Fourth Quarter and Full Year 2023 Financial Results
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK(TM) Bispecific Antibody in the American Society of Hematology's Blood Journal
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
INVO Reports Record Third Quarter 2023 Financial Results
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.